Blockbuster weight loss drugs like Ozempic deliver big results but face big questions
Three major reviews commissioned by the World Health Organization find that GLP-1 drugs including tirzepatide (sold as Mounjaro and Zepbound), semaglutide (Ozempic and Wegovy), and liraglutide (Victoza and Saxenda) can lead to substantial weight loss in people with obesity. But while the results are impressive, researchers caution that most trials were funded by drugmakers, long term safety data are still limited, and side effects such as nausea are common.
Secondary Cardiovascular Disease Prevention With Semaglutide at Cash Price Is Cost-Effective
TUESDAY, Feb. 10, 2026 — Lowering the annual cost of semaglutide by 18 percent (from $8,604 to $7,055) or making the current cash price available to all patients would make semaglutide cost-effective, according to a study published online Feb. 4…
Hims & Hers Wegovy Knock-Off Pill Sparks Lawsuit After FDA Crackdown
Hims & Hers has withdrawn its low cost compounded weight loss pill after pressure from top U.S. health officials and a major lawsuit. Image courtesy of Novo Nordisk
Hims & Hers recently announced a $49 compounded semaglutide pill, offering a low cost alternative to the new Wegovy pill.
However, the compounded version was withdrawn from the market after pressure from the HHS and FDA.
Ozempic Pill Launching; Glucose Monitor Makers Warned; Thyroidectomy in Older Adults
(MedPage Today) — The FDA approved three doses — 1.5 mg, 4 mg, and 9 mg — of a new oral semaglutide formulation for diabetes (Ozempic tablets), Novo Nordisk announced.
An ad for Novo Nordisk’s weight loss pill version of semaglutide (Wegovy…
US FDA finds ad introducing Wegovy pill misleading
Novo Nordisk A/S’ television ad introducing the tablet form of its weight-loss drug, Wegovy (semaglutide), to American consumers didn’t pass regulatory muster.
GLP-1 drugs may protect the heart beyond weight loss, trial results suggest
With the use of GLP-1 medications on the rise, cardiologists are seeing benefits to heart health, and it might not all be related to weight loss alone. GLP-1 medications, including semaglutide, are a class of drugs that act on receptors throughout the body, influencing insulin sensitivity, appetite regulation, inflammation and metabolic health. These therapies traditionally were used to treat diabetes; however, weight loss is a well-recognized side effect, and they are now used for weight loss goals.
Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study
Kailera will launch a global Phase 2 study of ribupatide this year, while Hengrui will push the asset into Phase 3 in China.
New Novo Nordisk weight-loss drug more effective than Wegovy in clinical trial
Hims Pulls Cheaper Wegovy Pill After Federal Scrutiny
MONDAY, Feb. 9, 2026 — Hims & Hers says it will stop selling a low-cost copy of a new weight-loss pill made by Novo Nordisk, after federal officials raised concerns that the product may violate drug laws.
The online health company…
Novo Sues Hims & Hers Over Compounded Version of Oral Wegovy Pill
Novo Nordisk has sued Hims for allegedly violating patents protecting semaglutide, seeking potentially “hundreds of millions” in damages, John Kuckelman, the pharma’s general counsel, said. The wellness platform pulled its version of the drug just days after launching it.